Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Do not let complexity hide deterioration
Hypoxia, sepsis, acute coronary syndrome, stroke, hypoglycaemia, bleeding, acute kidney injury and medicine toxicity can appear as falls, confusion or loss of function in multimorbidity.
Action: Stabilise and investigate the acute syndrome, reconcile medicines and recent changes immediately, then revise chronic targets only after physiology, baseline, prognosis and the person's goals are clear.
Synopsis
Integrate multiple long-term conditions around the person's priorities, identify interacting disease and medicine harm, reduce unmanageable treatment workload, and coordinate proportionate evidence-based care without abandoning beneficial treatment.
Multimorbidity means several conditions whose combined management materially affects daily life; counting diagnoses alone does not measure complexity.
Treatment burden includes dosing, monitoring, appointments, travel, self-management, adverse effects, equipment and work transferred to carers.
First-line review asks what matters most, identifies urgent problems and medicines, estimates benefit horizon and creates one prioritised plan.
Key red flags
A new symptom attributed to one known disease may represent a second emergency; avoid diagnostic overshadowing.
Medicine-related syndrome
Falls, confusion, anorexia, retention or postural symptoms emerge after cumulative or recently changed treatment.
Investigation priorities
01
Priority and burden interviewFirst step
Identify desired outcomes and the treatment work that threatens them.
Management branches
First-line reviewPrioritise, reconcile and identify harm
Several conditions or medicines create difficult decisions.
Treat urgent deterioration and ask which outcomes and burdens matter most to the person.
Reconcile treatment and assess interactions, benefit horizon, adverse effects, feasibility and monitoring ownership.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.